康希诺生物(06185.HK)新冠疫苗三期生产基地产品在天津下线
内地央视报道,康希诺生物(06185.HK)(688185.SH)宣布「康希诺生物新冠疫苗三期生产基地产品正式下线」。该生产基地占地约1.5万平方米。基地的生产车间采用康希诺生物具有自主知识产权的腺病毒载体技术平台,该平台具有快速制备病毒载体疫苗的能力,为应对新发、突发重大传染病疫情防控提供保障。
由康希诺生物股份公司与军事科学院军事医学研究院生物工程研究所合作研发的重组新型冠状病毒疫苗克威莎TM是国内目前获批上市唯一采用单针免疫的新冠疫苗。单剂接种可以快速实现免疫保护,缩短接种周期。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.